Showing 1 - 10 results of 10 for search '"4.3.2.1."', query time: 0.23s Refine Results
  1. 1

    4 3 2 1: A Listening by Priyanka Deshmukh

    Published 2020-06-01
    “…In his latest novel, 4 3 2 1, by making the reader count down in order to access the first page of the novel, almost like the opening of a piece of music with a 4/4 time signature, Auster calls attention to the sounds his words make, to their music, and to the orality of his prose. …”
    Get full text
    Article
  2. 2

    4 3 2 1, The Book of Endlessly Forking Paths by Ilana Shiloh

    Published 2020-06-01
    “…4 3 2 1, Paul Auster’s 2017 novel, is a creative exploration of counterfactual thinking – thinking about what might have been. 4 3 2 1 departs from the premise that “the real […] also consist[s] of what could have happened but didn’t”. …”
    Get full text
    Article
  3. 3
  4. 4

    Return to the 1960s: the Role of ‘68 in Paul Auster’s Life and Work by Jesper Præst Nielsen

    Published 2020-06-01
    “…Its main analytical focus is on Auster’s critique of the anti-authoritative ethos of his generation in the early fictional autobiography Moon Palace (1989), but it draws comparisons to his later work as well, including 4 3 2 1 (2017) and the autobiographies Hand to Mouth (1997) and Report from the Interior (2013). …”
    Get full text
    Article
  5. 5

    Isoflavones and Isoflavone Glycosides: Structural-Electronic Properties and Antioxidant Relations—A Case of DFT Study by Son Ninh The, Thanh Do Minh, Trang Nguyen Van

    Published 2019-01-01
    “…Antioxidant ability can be arranged in the following order: compounds (4) > (3) > (2) > (1). Of comprehensive structural analysis, flavonoids with 4′-methylation and 6-methoxylation, especially 7-glycosylation would claim responsibility for antioxidant enhancement.…”
    Get full text
    Article
  6. 6

    Performance evaluation of HMA using recycled brick powder as filler with Superpave aggregate gradation by Tamiru Habte, Getachew Kebede, Agon Elmer, Anteneh Geremew

    Published 2024-01-01
    “…The CSD filler in proportions of 4, 3, 2, 1, and 0 % was combined with RBP in proportions of 1, 2, 3, 4, and 5 %, respectively, to replace the 5 % CSD control mix. …”
    Get full text
    Article
  7. 7

    转染survivin对HLF细胞增殖及凋亡的影响 by 顾霞, 林汉良, 朱有凯, 张萌, 梁惠珍, 沈艳

    Published 2006-01-01
    “…HLF/SVN细胞凋亡指数(0.3%、1.0%、1.5%)皆低于HLF(0.9%、4.3%、2.1%)及HLF/K(0.8%、1.4%、2.8%)。细胞生长曲线示HLF/SVN细胞生长快于HLF和HLF/K,差异有统计学意义(P〈0.05)。…”
    Get full text
    Article
  8. 8

    Synthesis and Application of New Ruthenium Complexes Containing β-Diketonato Ligands as Sensitizers for Nanocrystalline TiO2 Solar Cells by Ashraful Islam, Surya Prakash Singh, Liyuan Han

    Published 2011-01-01
    “…The β-diketonato-ruthenium(II)-polypyridyl sensitizers, when anchored to nanocrystalline TiO2 films for light to electrical energy conversion in regenerative photoelectrochemical cells, achieve efficient sensitization to TiO2 electrodes with increasing activity in the order 5 < 4 < 3 ≈ 2 < 1. Under standard AM 1.5 sunlight, the complex 1 yielded a short-circuit photocurrent density of 16.7 mA/cm2, an open-circuit voltage of 0.58 V, and a fill factor of 0.64, corresponding to an overall conversion efficiency of 6.2%. …”
    Get full text
    Article
  9. 9

    Ultrasound analysis of hemidiaphragm function in case of pleural effusion by Martin Boussuges, Martin Boussuges, Fabienne Bregeon, Fabienne Bregeon, Xavier Benoit D’Journo, Alain Boussuges, Alain Boussuges

    Published 2025-01-01
    “…Excursion during deep inspiration was reduced by the amount of fluid (4.3 ± 2.1 cm for small effusions, 3.2 ± 1.7 cm for moderate effusions and 1.1 ± 1.8 cm for large effusions). …”
    Get full text
    Article
  10. 10

    Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohort o... by Aaron R. Hansen, Stephan Probst, Jean-Mathieu Beauregard, Benjamin L. Viglianti, Jeff M. Michalski, Scott T. Tagawa, Oliver Sartor, Ronald F. Tutrone, Orhan K. Oz, Kevin D. Courtney, Ebrahim S. Delpassand, Luke T. Nordquist, Medhat M. Osman, Kim N. Chi, Richard Sparks, Noble George, Sara M. Hawley, Wenting Wu, Jessica D. Jensen, Neil E. Fleshner

    Published 2025-01-01
    “…Mean (median, range) tumor specific absorbed dose was 4.3 (2.1, 0.3-33.4) Gy/GBq (approximately 29 Gy/cycle) based on planar + SPECT/CT of 21 lesions in seven participants. [177Lu]Lu-PNT2002 was associated with no treatment-related deaths, few treatment-related grade ≥3 treatment-emergent adverse events (TEAEs), and no discontinuations for unacceptable toxicity. …”
    Get full text
    Article